Heterogeneous-Nuclear Ribonucleoprotein U
"Heterogeneous-Nuclear Ribonucleoprotein U" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous-nuclear ribonucleoprotein found associated with the NUCLEAR MATRIX.
| Descriptor ID |
D034722
|
| MeSH Number(s) |
D12.776.157.725.813.750.800 D12.776.660.650.500 D12.776.664.962.813.750.800
|
| Concept/Terms |
Heterogeneous-Nuclear Ribonucleoprotein U- Heterogeneous-Nuclear Ribonucleoprotein U
- Heterogeneous Nuclear Ribonucleoprotein U
- Ribonucleoprotein U, Heterogeneous-Nuclear
- Scaffold Attachment Factor A (SAF-A)
- hnRNP U
- Glucocorticoid Receptor Interacting Protein 120
- GRIP120
|
Below are MeSH descriptors whose meaning is more general than "Heterogeneous-Nuclear Ribonucleoprotein U".
Below are MeSH descriptors whose meaning is more specific than "Heterogeneous-Nuclear Ribonucleoprotein U".
This graph shows the total number of publications written about "Heterogeneous-Nuclear Ribonucleoprotein U" by people in this website by year, and whether "Heterogeneous-Nuclear Ribonucleoprotein U" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterogeneous-Nuclear Ribonucleoprotein U" by people in Profiles.
-
circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression. J Exp Clin Cancer Res. 2023 Nov 23; 42(1):313.
-
Expanding the phenotype of HNRNPU-related neurodevelopmental disorder with emphasis on seizure phenotype and review of literature. Am J Med Genet A. 2022 05; 188(5):1497-1514.
-
Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat Commun. 2020 10 01; 11(1):4932.
-
HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression. J Hematol Oncol. 2020 03 26; 13(1):24.
-
Clinical and molecular characterization of de novo loss of function variants in HNRNPU. Am J Med Genet A. 2017 Oct; 173(10):2680-2689.